Calidi Biotherapeutics CLDI Cash Flow Statement (2021-2026)

NYSE CLDI
$0.67 -0.01 (-1.98%)
As of: Nov 11, 2026 · 2:54 PM EST
Reported Financials

Calidi Biotherapeutics Quarterly Cash Flow Statement

Periods 21 quarters
Latest Jun 2026

Calidi Biotherapeutics reported cash from operations of -$4.38M and free cash flow of -$4.42M for the quarter ended Jun 2026, up 10.2% year over year. This cash flow statement covers 21 quarters of results from Jun 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-0.82M4.29M-7.74M-4.58M-5.36M-7.76M-6.46M-12.50M-2.02M-8.23M-7.23M-5.77M-5.07M-4.15M-5.06M-5.76M-5.18M-4.06M-4.11M-4.16M
Depreciation and DepletionDep. & Depletion
0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.10M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
0.12M0.20M0.02M0.20M-0.28M0.02M0.02M0.01M0.00M
Depreciation & Amortization (CF)Dep. & Amort.
0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.10M0.39M0.39M0.10M0.10M0.42M0.43M0.10M
Share-based CompensationStock Comp.
1.06M1.06M1.43M1.08M1.11M1.19M0.89M0.75M0.69M0.63M0.61M0.52M0.53M0.45M0.23M0.16M
Gains from Investment SecuritiesGains Investment
0.00M0.00M0.00M0.13M0.03M0.01M0.20M-0.04M0.02M-0.05M0.00M
Other non-cash itemsOther Non-Cash
-0.28M-4.38M-2.09M-4.03M-0.46M-6.76M0.10M1.28M0.26M0.27M0.27M0.28M0.29M0.30M0.30M-0.32M0.10M
Change in Working Capital
Change in Account PayablesChange Payables
0.00M536.001.56M0.06M0.02M-1.69M-5.98M1.49M0.97M0.17M-0.61M-1.17M-0.75M0.02M-0.19M-0.40M0.23M0.07M
Change in Accrued ExpensesChange Accrued Exp.
-0.02M-0.01M2.03M-0.22M0.24M1.25M-0.79M0.58M-0.39M-0.71M-0.19M-0.57M-1.69M0.24M0.26M-0.81M-0.46M-0.28M
Change in Other Operating AssetsOther Assets Change
-0.79M1.51M-0.09M-0.11M-0.12M0.15M0.28M0.28M1.30M0.35M-1.58M-0.01M-0.47M0.25M0.32M-0.16M-0.12M0.00M0.07M0.26M
Change in Other Operating LiabilitiesOther Liabilities Change
0.04M-0.22M-0.23M1.28M-0.24M-0.25M-0.26M-0.27M-0.28M-0.49M-0.30M-0.31M-0.33M-0.34M
Other Working Capital ChangesOther WC Changes
0.79M-1.51M0.09M0.11M0.12M-0.15M-0.25M-0.50M-1.53M0.93M1.34M-0.24M0.21M-0.52M-0.60M-0.32M-0.19M-0.32M-0.39M-0.60M
Cash from OperationsCash from Ops.
117.22M0.51M-0.47M-0.27M-8.60M-3.88M-3.11M-5.17M-13.52M-5.19M-3.83M-5.49M-4.95M-5.42M-7.13M-4.88M-4.24M-5.05M-4.12M-4.38M
Investing Activities
Capital ExpendituresCapex
0.16M0.14M0.31M0.07M0.07M0.01M0.01M0.01M0.01M0.06M0.03M0.03M0.01M0.03M
Change in Property, Plant and EquipmentChange in PP&E
-0.16M-0.14M-0.31M-0.07M-0.07M-0.01M-0.01M-0.01M-0.01M-0.06M-0.03M-0.03M-0.01M-0.03M
Purchase of InvestmentsInvestments Purchased
460.00M0.43M0.93M
Sale and Maturity of InvestmentsInvestments Sold
190.01M
Other Investing Activities (as filed)Other investing (as filed)
0.04M
Cash from Investing ActivitiesCash from Investing
-0.33M-0.16M-0.14M-0.24M-0.06M-0.04M-0.01M-0.01M-0.01M-0.01M-0.06M-0.03M-0.08M-0.01M-0.03M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
2.40M0.65M0.75M0.50M3.20M0.60M
Long-Term Debt RepaymentsLT Debt Repayment
0.38M0.02M0.02M0.02M0.02M1.35M0.02M-1.18M0.02M0.02M1.47M0.39M0.40M0.03M0.04M0.05M
Net Long-Term Debt Issued (Repaid)Net LT Debt
-0.38M2.40M0.63M1.60M0.40M0.20M-1.47M-0.39M-0.40M-0.03M-0.04M-0.05M
Net Debt Issuances and RepaymentsNet Debt Issuance
-0.38M2.40M0.63M1.60M0.40M0.20M-1.47M-0.39M-0.40M-0.03M-0.04M-0.05M
Change in Capital Stock
Common Stock IssuedStock Issued
5.12M0.11M0.18M0.05M2.81M2.74M5.09M6.28M0.00M-2.78M3.27M0.01M1.99M
Net Shares Issued and RepurchasedNet Shares Issued
5.12M0.11M0.18M0.05M2.81M2.74M5.09M6.28M0.00M-2.78M3.27M0.01M1.99M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
0.17M
Net Equity Issued and RepurchasedNet Equity Issued
5.12M0.11M0.18M0.22M2.81M2.74M5.09M6.28M0.00M-2.78M3.27M0.01M1.99M
Other financing activities (as filed)
-0.56M-1.70M5.35M2.69M1.28M0.49M-3.27M-3.26M0.09M-0.88M1.73M-0.50M-0.30M-0.08M-0.34M-0.12M-0.17M-0.12M
Cash from Financing ActivitiesCash from Financing
7.77M4.32M3.79M6.58M21.64M-2.96M3.01M5.20M6.05M13.11M8.11M-0.47M9.48M0.34M5.16M1.83M
Additional items
Exchange Rate EffectFX Effect
0.01M0.02M-0.02M0.02M-0.01M-0.03M0.02M0.01M-0.01M0.00M
Change in Cash
-0.47M-0.27M-1.20M0.29M0.55M1.15M8.08M-8.20M-0.81M-0.31M1.06M7.69M0.97M-5.40M5.22M-4.78M1.03M-2.56M
Beginning Cash Balance
2.24M0.59M2.17M9.81M
Ending Cash Balance
1.20M1.06M0.60M0.33M0.04M0.09M0.08M0.67M10.37M1.36M1.05M2.12M10.78M5.38M10.59M6.85M4.29M
Free Cash FlowFCF
117.22M0.51M-0.47M-0.27M-8.60M-4.04M-3.24M-5.48M-13.59M-5.26M-3.84M-5.49M-4.95M-5.43M-7.14M-4.94M-4.27M-5.08M-4.12M-4.42M
Net Cash FlowNCF
117.22M0.51M-0.47M-0.27M-1.17M0.28M0.55M1.16M8.06M-8.18M-0.82M-0.29M1.09M7.68M0.97M-5.41M5.22M-4.79M1.04M-2.59M
Interest Paid
0.01M0.01M0.01M0.01M0.37M0.02M0.09M0.01M0.02M0.64M0.20M0.01M0.42M0.10M0.01M
Income Taxes PaidTaxes Paid
0.02M0.16M-0.16M0.00M0.01M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.01M0.01M0.00M

Calidi Biotherapeutics Cash Flow Statement API

Pull Calidi Biotherapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=CLDI&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY